Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

h and Development Expenses40--40Restructuring and Acquisition Integration Charges 22-(22)-Operating Income79-39118Interest Expense and Other, Net 23--23Income Before Income Tax56-3995Provision for Income Taxes20-1131Income from Continuing Operations36-2864Income from Discontinued Operations, Net of Tax2(2)---Net Income

$

38

$

(2)

$

28

$

64.Per Share Amounts:(4)Basic Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Diluted Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Weighted-Average Number of Common Shares Outstanding:Basic222.1222.1222.1222.1Diluted223.9223.9223.9223.9Effective Tax Rate34.4%n/a27.8%31.7%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations. 2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED SEGMENT FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2011Nonrecurring(in millions)GAAP Items(1)Adjusted(3)Medical SystemsRevenue$

509

$

-

$

509Operating Income $

88

$

7

$

95Procedural SolutionsRevenue$

335

$

-

$

335Operating Income $

20

$

4

$

24Quarter Ended September 30, 2010No
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Edison ... firm, announces the initiation of full coverage ... company developing and marketing products for orphan ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison ... the investment merits of BioAlliance Pharma, focusing ...
(Date:6/18/2013)...  Techne Corporation (NASDAQ: TECH ) ... acquire 100% ownership of Bionostics Holdings Limited and ... a global leader in the development, manufacture and ... operation of in vitro diagnostic (IVD) ... glucose and blood gas testing.  Biosnostics has strategic ...
(Date:6/18/2013)... Texas , June 18, 2013   ... ), a biopharmaceutical company focused on discovering breakthrough ... John Northcott has joined the company as ... operations. Mr. Northcott brings extensive commercial experience to ... across a variety of therapeutic areas. ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... therapy with Pfizer,s recently ... MALIBU, Calif., Nov. 15 Pathway Diagnostics announces,that ... U.S. Patent,number 7,294,458 (the ,458 patent) entitled "Analysis of ... Pathway Diagnostics,has licensed the ,458 patent (with rights to ...
... WYE ),today announced that its Board of Directors ... effective immediately. Mr. Davidson will,continue in his role as ... and divisional financial positions since joining the Company,in 1984. ... Chief,Financial Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth. ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that ... September 30, 2007. Net,revenues totaled $7,373,770 for the quarter ... in 2006. Gross profit decreased by 2.66% due to ... from Aida,s,transfusion and injection forms of etimicin sulfate increased ...
Cached Biology Technology:Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy 2Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:6/18/2013)... in the Gulf of Mexico and a smaller than ... based on several NOAA-supported forecast models. , NOAA-supported modelers ... the Louisiana Universities Marine Consortium are forecasting that ... be between 7,286 and 8,561 square miles which could ... range from an area the size of Connecticut, Rhode ...
(Date:6/18/2013)... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ... in 2006. He performed his Ph.D. thesis research ...
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... more serious threat to marine life than previously thought. ... (19 July) in the British Ecological Society,s Journal ... of turtles from across the Pacific are being captured ... fisheries in Peru, the study suggests that thousands of ...
... Those solar panels on top of your roof aren,t ... your workplace, too, according to a team of researchers led ... UC San Diego Jacobs School of Engineering. , In ... Solar Energy , Kleissl and his team published what they ...
... 2011) Researchers from the John Theurer Cancer Center ... cancer-related studies during the recently concluded American Society of ... 3 7, 2011 in Chicago. The studies examined ... outcomes, and patient quality of life issues. ...
Cached Biology News:Study shows small-scale fisheries' impact on marine life 2Solar Panels Keep Buildings Cool 2Solar Panels Keep Buildings Cool 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: